Working memory and short-term memory storage
9 Working memory and short-term memory storage What does backward recall tell us? Gerald Tehan Kaye Mills One of the recent issues for those interested in working memory is the…
What do working memory span tasks like reading span really measure?
Figure 2.1 (a) The all-components model. (b) The text + integration model. (p.37) Figure 2.1 (c) The text-only model. (d) The integration-only model.(p.38) the text-only model, one comparing the text + integration model…
Working memory
1 Working memory Past, present…and future? Alan Baddeley Graham Hitch As the longest serving residents of the province of working memory, the two of us have been invited to introduce…
Summary
© Springer International Publishing Switzerland 2015Raymond A. Huml (ed.)Muscular Dystrophy10.1007/978-3-319-17362-7_15 15. Summary Raymond A. Huml1 (1) Biosimilars Center of Excellence, Quintiles Inc., 4820 Emperor Boulevard, Durham, NC 27703, USA Raymond A. Huml Email: raymond.huml@quintiles.com Muscular dystrophy (MD)…
Global and National Patient Registries
© Springer International Publishing Switzerland 2015Raymond A. Huml (ed.)Muscular Dystrophy10.1007/978-3-319-17362-7_14 14. Global and National Patient Registries Raymond A. Huml1 (1) Biosimilars Center of Excellence, Quintiles Inc., 4820 Emperor Boulevard, Durham, NC 27703, USA Raymond A. Huml Email:…
U.S. Patient Advocacy Groups
(1) ℅ Raymond A. Huml, Quintiles Inc., 4820 Emperor Blvd, Durham, NC 27703, USA For newly diagnosed muscular dystrophy (MD) patients and their caregivers in the U.S., the first point…
Pharmaceutical Products and Non-pharmaceutical Interventions as Potential Treatments for Patients with Muscular Dystrophy
Fig. 12.1 FDA foundation building for clinical trial drug development As the scientific (e.g., pathophysiology, mechanism of action [MOA], effect of intervention) and clinical data (post IND phase, such as…
Key Challenges to the Approval of Products to Treat Patients with Muscular Dystrophy
Name of document Date released Report: complex issues in developing drugs and biological products for rare diseases and accelerating the development of therapies for pediatric rare diseases including strategic plan:…
